The Rationale for the Administering the Seviprotimut-L Vaccine to Patients with Melanoma
Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.